|

Understanding Mesothelioma: The Role of Calretinin Explored

ByHolly Zink
Understanding Mesothelioma: The Role of Calretinin Explored

Mesothelioma is a rare and tough cancer caused by asbestos. Researchers all over the world are studying to improve how we diagnose and treat it. In a recent study, scientists looked closely at calretinin. Calretinin is a protein that could be important in figuring out and predicting how mesothelioma behaves. Researchers explain the complexities and share what we’ve learned from studying calretinin.

Learning About Calretinin

Mesothelioma is a strong cancer that often starts in linings around important organs like the lungs, abdomen, and heart. It’s caused by exposure to asbestos, a harmful substance once widely used in construction.

Calretinin is a unique protein that researchers are investigating as a possible sign of mesothelioma. It could be a simple signal saying, “There might be mesothelioma here.” This new study aimed to find out if calretinin could tell us more about how the disease behaves and how it responds to treatment.

The study team looked at 265 people with mesothelioma. They measured calretinin levels in their blood and looked at specific genes connected to calretinin. The goal was to find clues about how the cancer behaves and reacts to different treatments.

Higher calretinin levels were linked to faster cancer growth and shorter overall survival. But when researchers considered other things about the patients, this link became less clear. Certain genes, like SEPTIN7 and MIR335, seemed to influence how long people survived. This is even when considering other various patient-related factors.

Calretinin and Chemotherapy

Results were tricky when they looked at patients going through cisplatin-based chemotherapy. These patients with high calretinin levels had a higher chance of cancer coming back. If calretinin levels went beyond a certain point, it meant a shorter time before cancer came back. This was regardless of other patient-related factors. The gene MIR335 seemed to be connected to how well people responded to chemotherapy.

Understanding mesothelioma is like solving a complicated puzzle. Calretinin seems to be an important piece. It not only helps find cancer but also gives us useful information about how it behaves and reacts to treatment. Ongoing research like this brings us closer to better ways of dealing with this tough cancer. As we uncover more about mesothelioma, calretinin could become a crucial tool in our ongoing fight against this challenging disease.

Source:

Zupanc, Cita, Alenka Franko, Danijela Strbac, Viljem Kovac, Vita Dolzan, and Katja Goricar. “Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.” INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 25, no. 1 (January 2024): 190. https://doi.org/10.3390/ijms25010190.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…